Methods and materials for reducing cardiac xenograft rejection
AssigneeMayo Foundation for Medical Education and Research
InventorsChristopher G.A. McGregor, Guerard W. Byrne
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine β1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous α-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.
Claims2
A transgenic pig wherein the somatic cells of said pig do not express a functional polypeptide having the amino acid sequence set forth in SEQ ID NO:1.
A transgenic pig wherein the somatic cells of said pig comprise a disruption in the nucleic acid sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:1, wherein said disruption prevents expression of a functional polypeptide having the amino acid sequence set forth in SEQ ID NO:1.
Dependencies are inferred from the claim text.